TME Pharma N.V. (0N6A) AI Stock Analysis

1 Followers

TME Pharma N.V.

(Frankfurt:0N6A)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Focused oncology expertiseConcentration on cancer, and particularly CNS malignancies, gives TME Pharma a defined therapeutic focus rather than a broad undifferentiated platform. Specialization can support coherent research priorities and deeper expertise as candidates progress through development over the next several quarters.

Negative Factors

Pre-commercial revenue baseA near-zero and inconsistent revenue base means TME Pharma currently lacks recurring commercial sales to fund operations. This leaves financial progress dependent on successful clinical development and eventual commercialization or partnering, both of which remain ahead of the current business.

TME Pharma N.V. (0N6A) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 10.28M
Dividend Yield: ―
Average Volume (3M): 78.12K
Price to Earnings (P/E): -6.3
Beta (1Y): -0.11
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 12
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

TME Pharma N.V. Business Overview & Revenue Model

Company Description

TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipelin...

TME Pharma N.V. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:0N6A against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:TNG	48Neutral	EUR 202.59M	-4.37	-29.36%	―	189.81%	38.50%
FR:IPH	47Neutral	EUR 154.82M	-2.60	152.56%	―	-29.48%	7.91%
FR:NANO	47Neutral	EUR 1.48B	-26.40	89.71%	―	―	―
FR:ALCLS	43Neutral	EUR 97.71M	-2.16	-94.14%	―	-5.98%	-8.67%
FR:OSE	37Underperform	EUR 40.84M	-1.01	-96.73%	―	-96.25%	-197.89%

* Healthcare Sector Average

Performance Comparison

DE:0N6A and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:0N6A	TME Pharma N.V.	0.10	0.03	51.47%
FR:IPH	Innate Pharma S.A.	1.33	-0.24	-15.33%
FR:NANO	Nanobiotix SA	29.04	9.48	48.47%
FR:TNG	Transgene SA	0.73	-0.57	-44.06%
FR:OSE	OSE Immunotherapeutics	1.70	-4.00	-70.14%
FR:ALCLS	Cellectis SA	1.28	-2.42	-65.36%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

TME Pharma N.V. AI Stock Analysis